The study by Zimdahl et al. [10] included 2229 individuals without diabetes, but at increased risk for type 2 diabetes (defined as a family history of type 2 diabetes, BMI of at least 27 kg/m2, impaired fasting glycemia, and/or previous gestational diabetes) and 979 patients with T2DM included in placebo-controlled phase III clinical trials, which assessed the safety and efficacy of the SGLT2-inhibitor empagliflozin. The gene discussed is SLC5A2; the disease is gestational diabetes.